Lilly has applied to U.S. drug regulators for emergency approval for its experimental Covid-19 antibody therapy, which previous data showed could reduce hospitalization rates. According to a statement Wednesday, the Indianapolis-based pharmaceutical giant has approached the U.S. Food and Drug Administration (FDA) about applying for emergency use authorizations for the treatment, which is owned by Lilly inc. and Canadian biotech company AbCellera Biologics Inc. Co-development.
If approved, high-risk patients who have recently been diagnosed with mild to moderate Covid-19 are expected to be able to receive the treatment.
Lilly is also working on a cocktail antibody therapy and expects to apply to regulators for authorization to use it in November, based on more data, and for full use approval in the second quarter of 2021.
According to lilly’s interim findings, the company and AbCellera’s experimental therapy, known as LY-Cov555, reduced the rate of hospitalization or emergency care for patients with symptoms compared to placebos. It also reduces viral load and other symptoms associated with infection with the new coronavirus.